Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19

Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19

The Receptor-Binding Domain (RBD) of the Spike (S) protein from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has glycosylation sites which can limit the production of reliable antigens expressed in prokaryotic platforms, due to glycan-mediated evasion of the host immune response. How...

Full description

Bibliographic Details
Main Authors: Leandro Núñez-Muñoz, Gabriel Marcelino-Pérez, Berenice Calderón-Pérez, Miriam Pérez-Saldívar, Karla Acosta-Virgen, Hugo González-Conchillos, Brenda Vargas-Hernández, Ana Olivares-Martínez, Roberto Ruiz-Medrano, Daniela Roa-Velázquez, Edgar Morales-Ríos, Jorge Ramos-Flores, Gustavo Torres-Franco, Diana Peláez-González, Jorge Fernández-Hernández, Martha Espinosa-Cantellano, Diana Tapia-Sidas, José Abrahan Ramírez-Pool, América Padilla-Viveros, Beatriz Xoconostle-Cázares
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Vaccines
Subjects:
SARS-CoV-2
receptor binding domain
Spike protein
vaccine
viral glycosylation
prokaryotic expression
Online Access:https://www.mdpi.com/2076-393X/9/8/928

Internet

https://www.mdpi.com/2076-393X/9/8/928

Similar Items